Our projects and activities are country-led and country-executed; they test interventions that generate evidence for policy and scalable practices to reduce drug-resistant infections.
Existing evidence to prevent and control antimicrobial resistance is often generated in high-income countries and not always applicable to LMICs. Little attention has been given to identifying what exact solutions are needed in local LMIC-settings. At ICARS, we use intervention and implementation research to test context-specific solutions for LMICs.
When microbes become resistant to antimicrobials such as antibiotics and start to spread, health systems are at risk.
Antimicrobial resistance (or AMR for short) is one of the greatest threats to health, society, and economies worldwide and the World Health Organisation has classified antimicrobial resistance in the top 10 threats to global health.
We envisage a world where drug-resistant infections are no longer a threat.
Our mission is to advance implementation of innovative and evidence-informed AMR solutions aligned with national strategic priorities in low-and middle-income countries through research, partnerships and capacity strengthening.
At ICARS we take a holistic One Health approach to creating evidence for policy and action to reduce AMR.
ICARS’ thematic portfolio explores the critical dimensions shaping the AMR landscape today, offering insights into the drivers, interventions, and innovations that will help safeguard health for people, animals, and the planet. Each theme highlights key challenges, ongoing research, and impactful projects supported by ICARS in low- and middle-income countries (LMICs).
